Oxaliplatin 100 mg/m2 iv on day 1, and capecitabine 1,000 mg/m2 orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previously unexposed to adjuvant chemotherapy (48%), while no correlation was found with the actually delivered oxaliplatin dose intensity. Overall, haematological side effects were negligible, with no case of grade 4 toxicity, and only one patient suffering from an episode of grade 3 neutropenic fever. Severe anaemia occurred in 4 (11%) patients, and grade 3 neuropathy affected 9 (24%) patients. Median progression-free survival was 7.9 (95% CI, 6.2-9.6) months, and median overall survival has not been reached yet. In conclusion, the OXXEL regimen resulted safe and active, and it deserves further evaluation in metastatic colorectal cancer patients.

P COMELLA, BMASSIDDA, PALMERI S, AFARRIS, LDE LUCIA, DNATALE, et al. (2005). ”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study”. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 56, 481-486 [10.1007/s00280-005-1003-6].

”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study”

PALMERI, Sergio;
2005-01-01

Abstract

Oxaliplatin 100 mg/m2 iv on day 1, and capecitabine 1,000 mg/m2 orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previously unexposed to adjuvant chemotherapy (48%), while no correlation was found with the actually delivered oxaliplatin dose intensity. Overall, haematological side effects were negligible, with no case of grade 4 toxicity, and only one patient suffering from an episode of grade 3 neutropenic fever. Severe anaemia occurred in 4 (11%) patients, and grade 3 neuropathy affected 9 (24%) patients. Median progression-free survival was 7.9 (95% CI, 6.2-9.6) months, and median overall survival has not been reached yet. In conclusion, the OXXEL regimen resulted safe and active, and it deserves further evaluation in metastatic colorectal cancer patients.
2005
P COMELLA, BMASSIDDA, PALMERI S, AFARRIS, LDE LUCIA, DNATALE, et al. (2005). ”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study”. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 56, 481-486 [10.1007/s00280-005-1003-6].
File in questo prodotto:
File Dimensione Formato  
Cancer chemo Pharmacol 2005 Biweekly Oxaliplatin.pdf

accesso aperto

Dimensione 190.49 kB
Formato Adobe PDF
190.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/12351
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 7
social impact